121 related articles for article (PubMed ID: 25888715)
1. Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling.
Menendez JA; Schroeder B; Peirce SK; Vellon L; Papadimitropoulou A; Espinoza I; Lupu R
J Natl Cancer Inst; 2015 Jun; 107(6):djv090. PubMed ID: 25888715
[TBL] [Abstract][Full Text] [Related]
2. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
Wong TW; Lee FY; Yu C; Luo FR; Oppenheimer S; Zhang H; Smykla RA; Mastalerz H; Fink BE; Hunt JT; Gavai AV; Vite GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6186-93. PubMed ID: 17062696
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
4. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
Seoane S; Montero JC; Ocaña A; Pandiella A
J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
[TBL] [Abstract][Full Text] [Related]
5. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
[TBL] [Abstract][Full Text] [Related]
6. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.
Takai N; Jain A; Kawamata N; Popoviciu LM; Said JW; Whittaker S; Miyakawa I; Agus DB; Koeffler HP
Cancer; 2005 Dec; 104(12):2701-8. PubMed ID: 16265675
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
8. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
9. Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2.
Menendez JA; Vazquez-Martin A; Oliveras-Ferraros C; Garcia-Villalba R; Carrasco-Pancorbo A; Fernandez-Gutierrez A; Segura-Carretero A
Int J Oncol; 2009 Jan; 34(1):43-51. PubMed ID: 19082476
[TBL] [Abstract][Full Text] [Related]
10. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
Colomer R; Montero S; Lluch A; Ojeda B; Barnadas A; Casado A; Massutí B; Cortés-Funes H; Lloveras B
Clin Cancer Res; 2000 Jun; 6(6):2356-62. PubMed ID: 10873087
[TBL] [Abstract][Full Text] [Related]
11. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.
Pérez-Gómez E; Andradas C; Blasco-Benito S; Caffarel MM; García-Taboada E; Villa-Morales M; Moreno E; Hamann S; Martín-Villar E; Flores JM; Wenners A; Alkatout I; Klapper W; Röcken C; Bronsert P; Stickeler E; Staebler A; Bauer M; Arnold N; Soriano J; Pérez-Martínez M; Megías D; Moreno-Bueno G; Ortega-Gutiérrez S; Artola M; Vázquez-Villa H; Quintanilla M; Fernández-Piqueras J; Canela EI; McCormick PJ; Guzmán M; Sánchez C
J Natl Cancer Inst; 2015 Jun; 107(6):djv077. PubMed ID: 25855725
[TBL] [Abstract][Full Text] [Related]
12. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
Baselga J; Seidman AD; Rosen PP; Norton L
Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):43-8. PubMed ID: 9110342
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
14. Role of HER2/HER3 co-receptor in breast carcinogenesis.
Way TD; Lin JK
Future Oncol; 2005 Dec; 1(6):841-9. PubMed ID: 16556064
[TBL] [Abstract][Full Text] [Related]
15. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
16. Biology of HER2 and its importance in breast cancer.
Yarden Y
Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
[TBL] [Abstract][Full Text] [Related]
17. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
Ghedini GC; Ciravolo V; Tortoreto M; Giuffrè S; Bianchi F; Campiglio M; Mortarino M; Figini M; Coliva A; Carcangiu ML; Zambetti M; Piazza T; Ferrini S; Ménard S; Tagliabue E; Pupa SM
J Cell Physiol; 2010 Oct; 225(1):256-65. PubMed ID: 20506359
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells.
Do MT; Kim HG; Choi JH; Khanal T; Park BH; Tran TP; Jeong TC; Jeong HG
Food Chem; 2013 Dec; 141(3):2591-9. PubMed ID: 23870999
[TBL] [Abstract][Full Text] [Related]
19. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Moasser MM; Basso A; Averbuch SD; Rosen N
Cancer Res; 2001 Oct; 61(19):7184-8. PubMed ID: 11585753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]